These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10185760)

  • 21. Top-paid execs at publicly traded healthcare industry companies. Ranked by total compensation for 2013 as reported to the U.S. Securities and Exchange Commission.
    Mod Healthc; 2014 Dec; Suppl():16. PubMed ID: 25831870
    [No Abstract]   [Full Text] [Related]  

  • 22. Are we living in the end of the blockbuster drug era?
    Debnath B; Al-Mawsawi LQ; Neamati N
    Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The management of the cost and utilisation of pharmaceuticals in the United Kingdom.
    Burstall ML
    Health Policy; 1997 Sep; 41 Suppl():S27-43. PubMed ID: 10174472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Public health and economic policy: financing the NHS.
    Smart T; Draper P
    Lancet; 1985 Nov; 2(8466):1233-5. PubMed ID: 2866304
    [No Abstract]   [Full Text] [Related]  

  • 25. India's pharmaceutical industry: hype or high tech take-off?
    Malhotra P; Lofgren H
    Aust Health Rev; 2004 Nov; 28(2):182-93. PubMed ID: 15527398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patent nonsense: evidence tells of an industry out of social control.
    Mintzberg H
    CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
    [No Abstract]   [Full Text] [Related]  

  • 28. The performance and problems of the Turkish pharmaceutical industry: is there a need to develop a national drug policy?
    Kisa A
    J Med Syst; 2001 Oct; 25(5):309-18. PubMed ID: 11508904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Study of Comparative Advantage and Intra-Industry Trade in the Pharmaceutical Industry of Iran.
    Yusefzadeh H; Rezapour A; Lotfi F; Ebadifard Azar F; Nabilo B; Abolghasem Gorji H; Hadian M; Shahidisadeghi N; Karami A
    Glob J Health Sci; 2015 Apr; 7(6):295-307. PubMed ID: 26153184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NICE proposes faster process to appraise cheaper drugs.
    Mayor S
    BMJ; 2016 Oct; 355():i5592. PubMed ID: 27797748
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 32. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do market components account for higher US prescription prices?
    Monaghan MJ; Monaghan MS
    Ann Pharmacother; 1996 Dec; 30(12):1489-94. PubMed ID: 8968463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valued lives: Britain stirs outcry by weighing benefits of drugs versus price; government arm finds pills for Alzheimer's too costly, angering patients, Pfizer.
    Whalen J
    Wall St J (East Ed); 2005 Nov; ():A1, A11. PubMed ID: 16502534
    [No Abstract]   [Full Text] [Related]  

  • 36. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
    Freemantle N
    Health Policy; 1999 Mar; 46(3):255-65. PubMed ID: 10351671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pay increase for Scotland's NHS staff puts them ahead of others in UK.
    Nurs Stand; 2015 Mar; 29(29):8. PubMed ID: 25783238
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of Brexit on UK and EU Drug Regulation and Patient Access.
    Breckenridge A; Feldschreiber P
    Clin Pharmacol Ther; 2019 Apr; 105(4):923-925. PubMed ID: 30346627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Chinese medicines market: moving towards a market system?
    Huttin C
    Health Policy; 1994 Sep; 29(3):247-59. PubMed ID: 10138727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Careful use of science to advance the debate on the UK Cancer Drugs Fund.
    Lakdawalla DN; Jena AB; Doctor JN
    JAMA; 2014 Jan; 311(1):25-6. PubMed ID: 24381964
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.